Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
In this survey, to collect the safety and efficacy information of Amlodipine /Atorvastatin
 (Caduet® Combination Tablets) in daily medical practice will be examined. In addition, the
 necessity of special Investigation and post-marketing clinical studies will be examined,
 while investigating unexpected adverse drug reactions during the survey period and
 understanding of the status of frequency of adverse drug reactions in daily medical practice.
All the subjects whom an investigator prescribes the first Amlodipine /Atorvastatin (Caduet®)
 Combination Tablets should be registered consecutively until the number of subjects reaches
 target number in order to extract patients enrolled into the investigation at random.
Inclusion Criteria:

 -  Male or Female subjects intend to treat their cardiovascular disease who are
 prescribed Amlodipine /Atorvastatin (Caduet®) Combination Tablets by their Physicians

 Exclusion Criteria:

 Subjects who have been prescribed Amlodipine /Atorvastatin (Caduet®) Combination Tablets
 before.